samedan logo
 
 
spacer
home > pmps > summer 2019 > why so persitently unruly?
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Why so Persitently Unruly?

Given how vital the practice is to international regulatory compliance and to keeping products safely on the market, it may be expected that global life sciences firms would have the production and management of patient-facing materials efficiently coordinated so that accuracy and speed to market were taken for granted. Nothing could be further from reality.

Undoubtedly, the global labelling management burden in life sciences has soared in recent years. Companies’ R&D ambitions are growing, businesses are expanding into more markets, and regulators are steadily strengthening safety requirements to protect patients from harm. Each time the benefit/risk profile or safety factors change, or as regional or local regulatory agencies update their standards, international biopharmaceutical firms must react swiftly with accurate, compliant labelling for all affected markets. If they fail to do so, they risk delays to shipping or even to keeping their product registrations on the market, with implications for sales, revenues, and reputation.

Given that all of these market conditions are set to intensify rather than diminish, finding a solution sooner is now a priority. Balancing market opportunity, risk, and cost is becoming increasingly tough to do, so it is unsurprising that organisations are keen to bring the situation under control. As the frequency of changes increases − due to ever-growing product complexity, heightened pharmacovigilance, and new regulatory specifications – the demand soars exponentially.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Agnes Cwienczek is a Senior Life Sciences Consultant at AMPLEXOR with a remit that includes the provision of business process and data management expertise in the areas of regulatory information management, document management, and submission management. Prior to joining AMPLEXOR, she worked at Merck in its Global Regulatory and Quality Assurance department. Agnes received her Master’s degree in Information Management from the University of Koblenz-Landau, Germany.
spacer
Anges Cwienczek
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Neopac’s Polyfoil MMB® Tube Approved by USA’s Association of Plastic Recyclers

Oberdiessbach, Switzerland – Hoffmann Neopac, a global provider of high-quality packaging for pharma, beauty and oral care, has been granted approval for its Polyfoil® MMB mono-material barrier tube by the US-based Association of Plastic Recyclers. Offering a groundbreaking combination of product protection, user friendliness and appealing aesthetics, the tubes passed muster both with and without its thin film metallization option.
More info >>

White Papers

Backward Thinking: The Reverse Engineering of A Pressurized Metered Dose Inhaler

Development of a generic equivalent to a current marketed pressurized metered dose inhaler (pMDI) product brings immense challenges. Thorough analysis is critical to gain a comprehensive understanding of the physical attributes and pharmaceutical performance of the reference marketed product. Many factors need to be assessed, understood and combined in order to successfully develop a generic pMDI which will meet the regulatory and quality requirements as an equivalent product in the anticipated target market. Significant information about the reference marketed product can be obtained from a thorough review of published literature, specifically the Summary of Product Characteristics (SPC) and Patient Information Leaflet (PIL). Additionally, baselining the reference marketed product for pharmaceutical performance offers a working target specification for in-vitro correlation. It will ensure the smoothest possible path to commercialization and maximize return on investment. In addition, baselining of the reference marketed product is done to understand batch-to-batch variability and product performance over the stated shelf life to establish targets for critical quality attributes (CQAs), which can be applied to the generic equivalent pMDI.
More info >>

 
Industry Events

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022)

20-21 June 2022, Berlin, Germany

Pharmaceutical Manufacturing & Packaging Congress (PHARMAP 2022) is held on June, 20-21, 2022 in Berlin, Germany. The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies to discuss the manufacturing and packaging processes of the pharmaceutical industry. Among the participating companies are Bayer, Sandoz, Merck, Novartis, Roche, Genveon, Samsung Biologics, Pfizer.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement